Zymeworks Company Information



Jobs at Zymeworks

About this company:

URL: zymeworks.com

Legal Name: Zymeworks Inc.

Primary Location: 1385 W 8th Ave #540, Vancouver, BC V6H 3V9, Canada Map

Legal Name: Zymeworks Inc.

Industry/Sector: Biotechnology

Subindustry: Biotechnology

Related Tags: Biotechnology, Pharmaceuticals, B2B, SAAS, Pharmaceuticals, Biotechnology & Life Sciences

Employees: 150

Year Founded: 2003



Company Description

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's ...


jobs available

58 days

average time to fill role

51 / 100

remote work rating

Internal job site https://zymeworks.com/careers/overview
External job sites https://jobs.jobvite.com/zymeworkscareers
Job roles over time
Company Location Map
Image Name Title Description
user-pic Ali TehraniFounder, President & CEOAli Tehrani is one of Zymeworks' co-founders and currently serves as President and CEO of the company. He has been an integral part of many of the Company's corporate achievements including raising seed and angel financing and overseeing the Company's technical operations and patent filings. Dr. Tehrani has served on the MITACS Industrial Advisory Board, and BIOTECanada's Industrial and Environmental Committee. Currently, he is a member of the Board of Directors of LifeSciences British Columbia
user-pic Surjit DixitChief Technology OfficerDr. Dixit is Zymeworks' Chief Technology Officer, responsible for the implementation of novel algorithms and advancement of the ZymeCAD™ platform. Prior to joining Zymeworks, Dr. Dixit was the coordinator of Computational Molecular Biophysics at Weselyan University, Connecticut, USA, where he was instrumental in the development of novel methods for management and mining of high throughput molecular dynamics simulation data.
user-pic Tony PolverinoEVP Early Development & CSOAnthony (Tony) Polverino, Ph.D., joined Zymeworks in September 2018 and currently serves as our Executive Vice President of Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2018, Dr. Polverino was at Kite Pharma, Inc., which was acquired by Gilead Sciences, Inc. in 2017. While at Kite he served as the interim Chief Scientific Officer and before that as Vice President of Research. During his tenure, Yescarta®, Kite's lead chimeric antigen receptor (CAR)-
user-pic Neil KlompasChief Financial OfficerMr. Klompas is Zymeworks' Chief Financial Officer, and brings over 20 years of healthcare and biotechnology experience to Zymeworks' management team. Additionally, in conjunction with the CEO, he manages Zymeworks' corporate growth initiatives including corporate alliances, licensing and partnerships. Prior to joining Zymeworks he worked with KPMG LLP in Canada and the US, most recently with KPMG's Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton N
user-pic Nina WeisserPrincipal Scientist, OncologyNina Weisser is a Senior Scientist, Preclinical Research and Development at Zymeworks.
user-pic John BabcookSenior Vice President, Discovery ResearchBabcook has served as our Senior Vice President, Discovery Research since March 2016 and is responsible for target, antibody and drug conjugate discovery and associated partnerships. For over 20 years, Mr. Babcook has made significant contributions to the international biopharmaceutical industry. Mr. Babcook co-founded ImmGenics Pharmaceuticals Inc. in November 1998, based on a novel antibody generation platform. ImmGenics which was acquired by Abgenix Inc. in 2000 and subsequently by Amgen, Inc
Data Point Information
Funding Type Funding Raised Announced On Funding Series
angel $ 1.3 million March 03 2008
venture $ 3.2 million June 29 2009
venture $ 8.1 million September 22 2011
venture $ 11 million September 06 2012
venture $ 15 million January 09 2014
venture $ 23.99 million January 13 2015
venture $ 1.79 million February 27 2015
venture $ 61.5 million January 08 2016 A
Logo Investor Name Description
user-pic Northleaf Capital Partners Northleaf Capital Partners Ltd. ("Northleaf") is Canada's largest independent global private equity fund manager and advisor. Northleaf's predecessor, TD Capital Private Equity Investors, was the private equity fund of funds and co-investment arm of TD Bank Financial Group, one of North America's leading financial institutions. Northleaf's clients include corporate and public pension plans, endowments, foundations, government agencies, financia
user-pic B D C Healthcare Venture BDC Healthcare Venture is a venture capital firm specializes in healthcare investments. The firm prefers to invest in the innovative therapeutics, medical technology, health technology, prevention, diagnostics, personalized treatment, mobile technologies and services, robotics, automation and disease management sectors.
user-pic Fonds de solidarité F T Q Fonds de solidarité FTQ is a private equity and venture capital firm specializing in investments in start-ups, early venture, mergers, business acquisitions, management buyouts, market development project or a buyout, financing for new programs, organic g
user-pic Brace Pharma Brace Pharma Capital is a strategic investment company formed by EMS S/A, the largest pharmaceutical company in Brazil, and high net worth biotech investors. We invest in innovative, life changing therapies for diseases with a high degree of unmet medical
user-pic Celgene Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hem
user-pic C T I Life Sciences Fund Based in Montréal, CTI Life Sciences, a Canadian venture firm makes venture capital investments in high quality emerging life sciences companies at the pre-clinical and clinical development stage in Canada and in the U.S. CTI Life Sciences currently manag
user-pic Lumira Ventures With a 30-year reputation as a leading North American healthcare and life sciences venture capital firm, with offices in Toronto, Montreal, Vancouver and Boston, Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meeting significant unmet needs and creating transformation impact in communities worldwide. Since 1989, Lumi
user-pic Teralys Capital
user-pic Advanced Biotechnologies Venture Fund Advanced Biotechnologies Venture Fund is a boutique venture fund investing in leading-edge opportunities in the biotechnology, medical device, healthcare IT & specialty pharmaceutical sectors. ABVF is focusing its investments in promising companies tha
user-pic Merlin Nexus Merlin Nexus, based in New York, is a company focused on crossover private equity investing in the life sciences industry. Merlin Nexus invests globally in private and public healthcare companies. With its first fund launched in 2001 by Dominique Sémo
Similar Company URL
MorphoSys morphosys.com
LifeSciences BC lifesciencesbc.ca
Xencor xencor.com
Recruiter Name Recruiter Title Recruiter Email

To sign up, click register for an account.